Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12273445 | 1.00 | LIPE (1.00) | LIPE | |
| SCHEMBL12274179 | 0.93 | LIPE (1.00) | LIPE | |
| SCHEMBL12274178 | 0.93 | LIPE (1.00) | LIPE | |
| SCHEMBL12273453 | 0.89 | LIPE (1.00) | LIPE | |
| SCHEMBL12273457 | 0.89 | LIPE (1.00) | LIPE | |
| SCHEMBL12273894 | 0.89 | LIPE (1.00) | LIPE | |
| SCHEMBL12273847 | 0.89 | LIPE (1.00) | LIPE | |
| SCHEMBL12273848 | 0.89 | LIPE (1.00) | LIPE | |
| SCHEMBL12273889 | 0.87 | LIPE (1.00) | LIPE | |
| SCHEMBL12273603 | 0.87 | LIPE (1.00) | LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722721-B2 | SEC-hydroxycyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-05-13 | — | — | US | claimed |
| EP-2686299-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES AS HSL INHIBITORS FOR THE TREATMENT DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-22 | — | — | EP | claimed |
| US-20120238613-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | claimed |
| WO-2012123432-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES AS HSL INHIBITORS FOR THE TREATMENT DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | claimed |
| US-8722721-B2 | SEC-hydroxycyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722721-B2 | SEC-hydroxycyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722721-B2 | SEC-hydroxycyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2686299-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES AS HSL INHIBITORS FOR THE TREATMENT DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-20120238613-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238613-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238613-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | disclosed |
| WO-2012123432-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES AS HSL INHIBITORS FOR THE TREATMENT DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012123432-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES AS HSL INHIBITORS FOR THE TREATMENT DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238613-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES | SEC61B, SEC61A1, SEC22B | LIPE 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.